Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes

Özen ÖZ GÜL; Soner CANDER

doi:https://doi.org/10.46310/tjim.1070223

Makale detayları

Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes

Yazarlar:

Özen ÖZ GÜL | Soner CANDER

Yayıncı:

Nizameddin KOCA

Ana Başlıklar:

Hastalıklar

Dergi:

Turkish Journal of Internal Medicine 2022 Vol.4, pp.34-40

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000637603

Sıklık:

Üç Aylık

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.1070223

Özet:

 

Introduction: The specific association between sitagliptin and Fibroblast Growth Factor-19 (FGF19) is yet to be clarified. In this study, we aimed to investigate the effect of sitagliptin therapy on the levels of FDF19 in patients with type 2 diabetes mellitus (T2DM). 
Methods: A total of 35 patients newly diagnosed type 2 diabetes, and who had not received antidiabetic treatment before were included in this study. Sitagliptin therapy was administered as 100 mg/day. Patients’ demographic, anthropometric features, glycaemic variables, lipid profiles and FGF19 values were  evaluated at the baseline and at the 3rd month of the treatment and the obtained data were compared. 
Results: The mean age of the patients was 53.34 ± 8.09 years. The mean weight, body mass index (BMI), hip circumference, postprandial blood glucose and glycosylated haemoglobin A1c (HbA1c) values were statistically significantly lower at the 3rd month of the treatment compared to the baseline values (for all, p<0.05). The mean FGF19 was found as 84.37±64.23 pg/mL at the baseline and 86.06±44.10 pg/mL at the 3rd month of the treatment and the difference was not statistically significant (p=0.789). A moderate negative correlation was found between FGF19, total cholesterol and low density lipoprotein cholesterol (LDL-c), and a moderate positive correlation between FGF19 and triglycerides. 
Conclusion: This study did not show a significant effect of sitagliptin therapy on FGF19. T2DM variables such as postprandial blood glucose and HbAc1 were significantly improved. FGF19 was moderately correlated with total cholesterol and LDL-c in negative direction and with triglycerides in positive direction.

Makale detayları

Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes

Yazarlar: Özen ÖZ GÜL | Soner CANDER

Yayıncı: Nizameddin KOCA

Ana Başlıklar: Hastalıklar

Dergi: Turkish Journal of Internal Medicine 2022 Vol.4, pp.34-40

Belge Tipi: Makale

Yayın Tarihi: 3/2022

Belge Dili: İngilizce

Document ID (Org No.): 2000637603

Sıklık: Üç Aylık

eISSN: 2687-4245

DOI: https://doi.org/10.46310/tjim.1070223

Sayı

Yazarlar:

Özen ÖZ GÜL | Soner CANDER

Yayıncı:

Nizameddin KOCA

Ana Başlıklar:

Hastalıklar

Dergi:

Turkish Journal of Internal Medicine 2022 Vol.4, pp.34-40

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000637603

Sıklık:

Üç Aylık

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.1070223